Down 35%! Spectrum Pharmaceuticals, Inc. (SPPI) Is a Biotech Trainwreck: Sagent Pharmaceuticals Inc (SGNT), Teva Pharmaceutical Industries Ltd (ADR) (TEVA)

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) is hurting today after dialing back guidance for the year. Apparently the increased production by Sagent Pharmaceuticals Inc. (NASDAQ:SGNT) of generic leucovorin, a less purified version of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)’s Fusilev, is cutting into Fusilev sales .

Don’t say I didn’t warn you.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI).October 2011: “How do you guess when Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and others will get their act together? And then when — dare I say, if — they do, how do you estimate how many doctors will head back to the generic?”

July 2012: “If you can confidently say that Fusilev sales are here to stay for the long term, Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) is probably a good buy at this point. I don’t have that confidence.”

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) claims that doctors actually want to buy the product, but that hospitals that stock the drug are cutting back on Fusilev now that the generic is more readily available.

The biotech is guiding for Fusilev sales of $10 to $15 million for the first quarter of the year, and approximately $80 to $90 million for the full year 2013. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) claims sales will stabilize in the second half as inventory is drawn down and sales match demand.

That could be wishful thinking. Even if it hits that goal, assuming $30 million in the first half and $50 million in the second half, we’re still a run rate of just half the over $200 million worth of Fusilev sold last year.

Fusilev is Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)’s top-selling drug by far, so the drop in sales hurts overall sales. Last month, Spectrum guided for 2013 revenue above the $268 million it brought in last year. Now it’s looking for revenue in the $160 million to $180 million range.

If Spectrum can stabilize sales and get things moving back in the right direction, it might be worth picking through this train wreck looking for some value. But that’s a pretty monumentous task. Risk-adverse investors would be best off watching from the sidelines for a few quarters until things stabilize.

The article Down 35%! This Is a Biotech Trainwreck originally appeared on Fool.com.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

The 10 Longest Wars of All Time

The 13 Worst Looking Foods that Taste Great

The 6 Most Gruesome Injuries Suffered During a Sports Match

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!